Literature DB >> 15541325

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.

Francesco Passamonti1, Elisa Rumi, Ester Pungolino, Lucia Malabarba, Paola Bertazzoni, Marina Valentini, Ester Orlandi, Luca Arcaini, Ercole Brusamolino, Cristiana Pascutto, Mario Cazzola, Enrica Morra, Mario Lazzarino.   

Abstract

PURPOSE: To assess life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.
METHODS: The study sample consisted of 831 consecutive patients with polycythemia vera (n = 396; 4184 person-years of follow-up) or essential thrombocythemia (n = 435; 4304 person-years of follow-up). Mortality in each group was compared with the Italian population using the standardized mortality ratio (SMR) based on life expectancy data obtained from the Italian Institute of Statistics.
RESULTS: The 15-year survival was 65% in patients with polycythemia and 73% in those with thrombocythemia. By Cox regression analysis, the independent predictors of death were a history of thrombosis for polycythemia (hazard ratio [HR] = 2.2; P = 0.0002) and thrombocythemia (HR = 2; P = 0.01), and male sex (HR = 1.8; P = 0.03) for thrombocythemia. Mortality compared with the general population was 1.6-fold higher (P <0.001) in patients with polycythemia but was not increased in those with thrombocythemia (SMR = 1; P = 0.8).
CONCLUSION: Life expectancy of patients with polycythemia vera (especially if younger than 50 years) was reduced compared with the general population, whereas life expectancy of patients with essential thrombocythemia was not affected significantly by the disease, reflecting the more indolent nature of the proliferation. History of thrombosis was the main predictor of death in both diseases.

Entities:  

Mesh:

Year:  2004        PMID: 15541325     DOI: 10.1016/j.amjmed.2004.06.032

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  104 in total

1.  Treatment outcome in a cohort of young patients with polycythemia vera.

Authors:  Marco Ruggeri; Silvia Finotto; Stefania Fortuna; Francesco Rodeghiero
Journal:  Intern Emerg Med       Date:  2010-07-06       Impact factor: 3.397

Review 2.  Primary thrombocytosis in children.

Authors:  Nicole Kucine; Katherine M Chastain; Michelle B Mahler; James B Bussel
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 3.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

4.  Left main coronary thrombosis with essential thrombocythemia.

Authors:  Zekeriya Nurkalem; Nevzat Uslu; Sevket Gorgulu; Mehmet Eren
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

Review 5.  Anagrelide: a review of its use in the management of essential thrombocythaemia.

Authors:  Antona J Wagstaff; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Splenic and Portal Vein Thrombosis With Concurrent Splenic Infarction: A Rare Manifestation of Essential Thrombocythemia.

Authors:  Manisha Gulia; Neha Sharma; Yajur Arya; Arshi Syal; Monica Gupta
Journal:  Cureus       Date:  2021-06-20

Review 7.  Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.

Authors:  Matjaz Sever; Kate J Newberry; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2014-03-17

8.  Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia.

Authors:  Rajesh Shrestha; Smith Giri; Ranjan Pathak; Vijaya Raj Bhatt
Journal:  World J Clin Oncol       Date:  2016-08-10

9.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Authors:  Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

Review 10.  Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.

Authors:  Ehab Atallah; Srdan Verstovsek
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.